https://www.selleckchem.com/mTOR.html ctiveness of NIV should not be limited to the assessment of blood gas correction. Several markers of oxygenation are used as prognostic markers in acute hypoxemic respiratory failure. Real-world use is limited by the need for invasive measurements and unreliable availability in the electronic health record. A pragmatic, reliable, and accurate marker of acute hypoxemic respiratory failure is needed to facilitate epidemiologic studies, clinical trials, and shared decision-making with patients. F is easily obtained at the bedside and from the electronic health record. The F trajectory may be a valuable marker of recovery in patients with acute hypoxemic respiratory failure. This was a historical cohort study of adult subjects admitted to an ICU with acute hypoxemic respiratory failure secondary to community-acquired pneumonia and/or ARDS. Our study included 2,670 subjects. F and S were consistently more available than was P in the electronic health record (F vs S vs P 100 vs 100 vs 72.8% on day 1, and 100 vs 99 vs 21% on day 5). A worsening F trajectory was associatede. FIO2 and SpO2 /FIO2 are pragmatic and readily available intermediate prognostic markers in acute hypoxic respiratory failure. The FIO2 trajectory in the first 5 d of ICU admission provided important prognostic information (ventilator-free days). Although the SpO2 /FIO2 trajectory was also associated with ventilator-free days, it did not provide more information than the FIO2 trajectory alone. Although pathogenic 22q11.2 deletions are an important cause of developmental delays and lifelong disease burden, their variable and complex clinical expression contributes to under-recognition, delayed molecular diagnosis and uncertainty about prevalence. We sought to estimate the contemporary live-birth prevalence of typical 22q11.2 deletions using a population-based newborn screening sample and to examine data available for associated clinical features. Using DNA available f